Bayer says it has signed an agreement to acquire all of the shares of Steigerwald Arzneimittelwerk (Darmstadt, Germany), a privately held pharmaceutical company specializing in pharmacy-only herbal medicines. Financial details of the deal have not been disclosed. Steigerwaldâ€™s product portfolio includes Iberogast for the treatment of functional gastrointestinal disorders and Laif for the treatment of mild to moderate depression. The transaction is expected to close in July. Steigerwald generated sales of â‚¬61.3 million ($79 million) in 2012. The company...
Access is for Chemweek 24/7 PLUS Members ONLY
This information is only available to Chemweek 24/7 PLUS members who have subscribed to Chemweek’s Business Daily. If you are a member, please log in, OR if you have a trial membership, please use your trial membership account information.
Forgot your user ID or password? Click here to have it sent to you.